iApneaMate S3

Home sleep testing (HST) with the S3 is appropriate for patients with high pre-test probability of moderate-to-severe OSA and no significant comorbidities that complicate diagnosis. This covers the majority of adult referrals, typically overweight patients presenting with snoring, witnessed apneas, and daytime sleepiness.

In-lab polysomnography (PSG) remains indicated for: suspected central sleep apnea, concurrent severe cardiopulmonary disease, neuromuscular disorders, pediatric patients, and cases where the home study is inconclusive or negative despite strong clinical suspicion. The practical advantage of HST: sleep labs in LATAM are scarce and expensive. Many markets have months-long PSG waitlists. The S3 lets clinicians diagnose and initiate treatment faster, at a fraction of the cost, in the patient's natural sleep environment, which often yields more representative data than a single night in an unfamiliar lab.

The S3 records six channels simultaneously during an overnight sleep study:

Nasal airflow (via pressure transducer): detects apneas, hypopneas, and flow limitation. Respiratory effort (thoracic and abdominal bands): differentiates obstructive events (effort present, airflow absent) from central events (effort absent). SpO2 (pulse oximetry): measures oxygen desaturation severity. Heart rate: captures cardiac response to apneic events. Body position: identifies positional OSA (worse supine). Snoring: correlates with upper airway resistance.

Together, these channels provide enough data to calculate the AHI (apnea-hypopnea index), classify event types, and grade OSA severity: the three outputs a clinician needs to make a treatment decision and prescribe PAP therapy.

The S3 is specifically designed for unattended, patient-applied use. Setup involves attaching the nasal cannula, finger pulse oximeter, thoracic/abdominal effort bands, and pressing start on the device's 1.77-inch display screen. Resvent provides illustrated quick-start guides in Spanish that walk patients through each step.

Most sleep programs hand the device to the patient at an afternoon appointment, demonstrate the setup in 10 to 15 minutes, and have the patient return the device the next morning. No overnight technician required. This is the entire economic advantage of home sleep testing: one device can cycle through 20 to 30 patients per month versus a PSG lab that tests one patient per bed per night. For wholesale buyers, each S3 unit generates revenue through repeated diagnostic use, not a one-time sale.

The American Academy of Sleep Medicine (AASM) classifies sleep diagnostic devices into four types based on the number and type of channels recorded. Type 3 devices monitor a minimum of four channels: airflow, respiratory effort, heart rate, and blood oxygen. These are the core parameters needed to diagnose obstructive sleep apnea (OSA) in an unattended setting.

The iApneaMate S3 exceeds this minimum with 6-lead monitoring: airflow, respiratory effort, SpO2, heart rate, body position, and snoring. Type 3 classification is the clinical threshold for insurance reimbursement in most LATAM markets. Type 4 devices (pulse oximetry only) are considered screening tools, not diagnostic. Hospitals and sleep clinics need Type 3 or higher to bill for home sleep testing. The S3's classification ensures the study results are accepted for treatment decisions and PAP therapy initiation.

Every positive OSA diagnosis generates a PAP therapy prescription. The S3 sits at the top of a revenue funnel: diagnose → prescribe → equip → supply consumables. A distributor who places S3 units in sleep clinics and pulmonology practices isn't just selling a diagnostic device: they're generating qualified demand for iBreeze CPAP, APAP, and BPAP systems downstream.

The math is straightforward: if an S3 unit processes 25 patients per month and the OSA positivity rate is roughly 70 to 80% in referred populations, that's 17 to 20 new PAP therapy candidates per device per month. Multiply that across a fleet of S3 units placed with your clinical accounts, and the downstream device and mask volume compounds rapidly. SysMed can structure bundle pricing for distributors running a full diagnostic-to-treatment pipeline.